ℹ️
🇨🇿
Hledání
Hledat publikace relevantní k dotazu "Patient-derived xenografts"
Patient-derived xenografts
Publikace
Předměty
Osoby
Publikace
Studium
Exportovat aktuální pohled
publication
Complex genetic and histopathological study of 15 patient-derived xenografts of aggressive lymphomas
2022 |
2. lékařská fakulta, 1. lékařská fakulta, Lékařská fakulta v Plzni, Fakulta tělesné výchovy a sportu
publication
Introducing in vivo pancreatic cancer models for the study of new therapeutic regimens
2022 |
1. lékařská fakulta, Lékařská fakulta v Plzni, 3. lékařská fakulta
publication
Quantitative In Vivo Monitoring of Hypoxia and Vascularization of Patient-Derived Murine Xenografts of Mantle Cell Lymphoma Using Photoacoustic and Ultrasound Imaging
2021 |
1. lékařská fakulta, Lékařská fakulta v Plzni
publication
Cytarabine nanotherapeutics with increased stability and enhanced lymphoma uptake for tailored highly effective therapy of mantle cell lymphoma
2021 |
1. lékařská fakulta
publication
Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
2015 |
2. lékařská fakulta
publication
3,5,7-Substituted Pyrazolo[4,3-d]Pyrimidine Inhibitors of Cyclin-Dependent Kinases and Cyclin K Degraders
2022 |
1. lékařská fakulta, Ústřední knihovna
publication
3,5,7-Substituted Pyrazolo[4,3-d]pyrimidine Inhibitors of Cyclin-Dependent Kinases and Their Evaluation in Lymphoma Models
2019 |
1. lékařská fakulta, Matematicko-fyzikální fakulta
publication
Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL
2017 |
1. lékařská fakulta
publication
mTOR inhibition amplifies the anti-lymphoma effect of PI3Kβ/δ blockage in diffuse large B-cell lymphoma
2023 |
1. lékařská fakulta, 3. lékařská fakulta
publication
Cotargeting of BCL2 with venetoclax and MCL1 with S63845 is synthetically lethal in vivo in relapsed mantle cell lymphoma
2019 |
2. lékařská fakulta, 1. lékařská fakulta
publication
Anti-CD38 Therapy with Daratumumab for Relapsed/Refractory CD20-Negative Diffuse Large B-Cell Lymphoma
2020